Ahead Of The Curve: Genetics Revolution For The Cf Care Team

Informações:

Sinopse

This 90-minutes symposium was presented at NACFC Anaheim 2011, offering information on the current treatment options for patients with cystic fibrosis, as well as information on emerging therapies. The topics include:- CFTR gene modifiers: what are they & how they work- The importance of the CFTR genotype/phenotype interaction- The role of gene modifiers in determining CF presentations- Using gene-targeted therapies to implement individualized treatment

Episódios

  • Seven Questions for the CF Care Team

    01/12/2011 Duração: 34min

    Presented at NACFC Anaheim 2011 this symposium presentation offers information on the current treatment options for patients with cystic fibrosis. Mike Boyle, MD, from Johns Hopkins University School of Medicine offers a 25-minute look at the basics of CF, then describes genotype and CF phenotype relationships. The presentation includes a review the influences of severity of lung disease and outcomes in CF, followed up by issues related to adherence.

  • Emerging Therapies and Implementing Individualized Treatments

    01/12/2011 Duração: 20min

    Presented at NACFC Anaheim 2011 this symposium presentation offers information on the current treatment options for patients with cystic fibrosis. Mike Boyle, MD, from Johns Hopkins University School of Medicine offers a 25-minute look at the basics of CF, then describes genotype and CF phenotype relationships. The presentation includes a review the influences of severity of lung disease and outcomes in CF, followed up by issues related to adherence.

  • Program Goals and Understanding the Relationships of CF Phenotype

    01/12/2011 Duração: 35min

    Presented at NACFC Anaheim 2011 this symposium presentation offers information on the current treatment options for patients with cystic fibrosis. Mike Boyle, MD, from Johns Hopkins University School of Medicine offers a 25-minute look at the basics of CF, then describes genotype and CF phenotype relationships. The presentation includes a review the influences of severity of lung disease and outcomes in CF, followed up by issues related to adherence.